Syn­dax Phar­ma­ceu­ti­cals won the first FDA ap­proval last week in a new class of med­i­cines called menin in­hibitors.

Regenxbio reported improved muscle function in boys with Duchenne muscular dystrophy using their gene therapy RGX-202. The ...

Novartis and Ratio Therapeutics announced a collaboration deal worth up to $745 million, focusing on SSTR2 radiotherapeutic ...

The FDA on Monday offered new draft guidance to help drugmakers understand the nuts and bolts of FDA processes for developing and submitting an application for a new cell or gene therapy, from pre-IND ...

Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate ...

Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...

At­las Ven­ture, one of biotech’s go-to VC firms, is eye­ing a $450 mil­lion 14th fund, part­ner Bruce Booth said in its ...

San Diego biotech Aven­zo Ther­a­peu­tics has in-li­censed an­oth­er as­set, this time se­cur­ing the glob­al ex-Chi­na ...

Cy­bin said its psilocin ana­log has the po­ten­tial to wipe out symp­toms in most pa­tients with a se­ri­ous form of ...

In 2010, neuroscientist and former Eli Lilly research leader Steve Paul started a company that he hoped would spark a revolution in drug discovery built around a class of compounds dubbed ...

Aclaris partners with Biosion for anti-TSLP programs and seeks $80M funding, Keymed Biosciences signs $626M potential deal with Ouro Medicines, ReCode receives CF Foundation funding, Quell gets $10M ...

In one of the most close­ly-watched are­nas in biotech, In­tel­lia says its gene edit­ing treat­ment for a heart mus­cle ...